Lonza Group AG

Core Business

Lonza Group is the world's largest contract development and manufacturing organization (CDMO), serving as the foundational manufacturing partner for the global CGT industry. In 2025, Lonza generated 6.53 billion Swiss francs ($7.4 billion) in revenue with a 31.6% EBITDA margin. The company scored a landmark achievement by winning the exclusive commercial manufacturing contract for CASGEVY at its Geleen, Netherlands facility — the first factory approved across FDA, EMA, and MHRA for CRISPR therapy production.

Global Presence

Headquartered in Basel, Switzerland, Lonza operates over 30 major facilities worldwide with approximately 20,000 employees. Key CGT hubs include Geleen (Netherlands), Portsmouth (New Hampshire), and sites across Europe, North America, and Asia. Lonza's multi-continent manufacturing footprint provides unmatched supply chain redundancy for its pharmaceutical clients.

Key Strengths

Lonza's unparalleled manufacturing scale, regulatory expertise, and technology diversity make it the partner of choice for both established pharmaceutical companies and emerging biotech firms. Its selection as the commercial manufacturer for CASGEVY validates its position at the pinnacle of CGT manufacturing capability. The 31.6% EBITDA margin demonstrates exceptional pricing power and operational efficiency in a capital-intensive industry.

VerityRank Score

Lonza Group achieves a VerityRank Score of 89/100, reflecting its dominant CDMO market position, unmatched global manufacturing footprint, and proven regulatory track record across multiple approved CGT products.

Lonza Group is the world's largest contract development and manufacturing organization, providing end-to-end CDMO services across mammalian cell culture, microbial fermentation, viral vector production, and cell therapy processing. With 30+ facilities across five continents and exclusive commercial manufacturing contracts for landmark therapies like CASGEVY, Lonza serves as the critical manufacturing backbone for the global pharmaceutical and biotech industries. The company achieved a 31.6% EBITDA margin in 2025.

• Mammalian and microbial cell culture contract manufacturing • Cell and gene therapy CDMO services viral vectors, plasmid DNA • Biologics drug substance and drug product manufacturing • Cell culture media and specialty biochemicals